Skip to main content

Paired Ends: Apr 14, 2009

Premium

Jonathan "Jack" Lord has been appointed as president and CEO of Navigenics and will assume his new position May 1. He replaces Mari Baker, who left the company in March. Lord joins Navigenics from Humana, where he was senior vice president and chief innovation officer. Prior to that, he was president of Health Dialog.


Lisa Wise has been named chief operating officer, and James O'Leary has been appointed chief innovation officer, a new position, of Genetic Alliance, a non-profit health advocacy organization.

Wiese has been with Genetic Alliance for more than five years, focusing on a variety of projects. Her new responsibilities will include integrating operations with new strategic demands of the organization. She holds bachelor's degrees in political science and media arts and a master's degree in communications from the University of Arizona.

O'Leary will direct strategic innovation as Genetic Alliance broadens its service to the genetics community.


Paul Keim has been appointed to the scientific advisory board of Febit. He is a senior investigator and director of the pathogen genomics division at the Translational Genomics Research Institute in Phoenix, Ariz., and a professor of biology at Northern Arizona University. Febit said Keim's expertise will be "particularly helpful in Febit's research activities in the field of biosecurity," and he will be a partner in developing new applications for the company's HybSelect sequence capture method.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.